Stay informed, stay ahead.
Biotech company Rani Therapeutics has signed a licensing agreement with Japan’s Chugai Pharmaceutical, worth up to $1.09 billion, to develop and market an oral version of a Chugai experimental antibody. Under the deal, Rani will receive an upfront $10 million, plus up to $75 million for development milestones and $100 million in sales milestones. Chugai…
Lead exposure remains one of the most widespread yet fully preventable global health threats, the World Health Organization (WHO) warned in a new statement. With the 13th International Lead Poisoning Prevention Week (19-25 October 2025) approaching, the agency declared that no level of lead is safe—especially for children. Children absorb lead more readily than adults….
The U.S. Food and Drug Administration (FDA) has expanded approval for Tezspire (tezepelumab-ekko), a drug co-developed by Amgen and AstraZeneca. Starting now, it can be used as a maintenance treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in people aged 12 and older. CRSwNP is a long-term sinus condition featuring inflammation and non-cancerous growths called…
Molecular diagnostics company BillionToOne is preparing to go public in the U.S., aiming for a valuation of up to $2.42 billion. Based in Menlo Park, California, the firm plans to offer up to 3.8 million shares at a price range of $49 to $55 each, raising as much as $211.5 million. BillionToOne develops advanced disease-diagnostic…
Shares of Danish drug maker Novo Nordisk sank about 5-6 % on Friday after U.S. President Donald Trump promised major price cuts for popular weight-loss treatments. The drop reflects investor fears that revenue from drugs like Ozempic and Wegovy might shrink. Trump, speaking at a White House event on drug costs and fertility treatments, singled…
AI tools are quickly entering doctors’ offices, clinics and hospitals as a way to reduce paperwork, speed diagnoses and help clinicians manage growing patient loads. Many doctors say AI could free up more time for direct patient care and cut administrative stress. AI is already being tested to write visit notes, summarize lab reports, flag…
The U.S. Food and Drug Administration (FDA) has selected nine drugs for expedited review under its new National Priority Voucher pilot program, designed to fast-track treatments that address major health needs. Instead of the typical 10–12 month review, these drugs could be approved in one to two months. The FDA says the program will use…
The White House and Merck KGaA announced an agreement Thursday aimed at dramatically reducing prices for in vitro fertilization (IVF) medications in the U.S. The effort is part of a broader push to make fertility treatment more affordable and accessible. Under the deal, Merck — via its U.S. arm EMD Serono — will offer key…
President Donald Trump said on Thursday that he plans to lower the price of Ozempic, signaling a sharp move in his administration’s broader campaign to reduce prescription drug costs. Speaking at a White House event focused on fertility treatments and drug pricing, Trump identified Ozempic as the drug he intended to target, saying “they’ll be…
Swiss pharma giant Roche is launching direct-to-consumer U.S. sales of its influenza treatment Xofluza priced at $50 per course, a steep 70% discount on its list price. The offering — available to both insured and uninsured patients — will be sold via same-day delivery services like Alto Pharmacy, Amazon Pharmacy, and Mark Cuban’s Cost Plus…
